MD4841B1 - Compuşi policiclici de carbamoilpiridonă şi utilizarea lor farmaceutică - Google Patents

Compuşi policiclici de carbamoilpiridonă şi utilizarea lor farmaceutică Download PDF

Info

Publication number
MD4841B1
MD4841B1 MDA20200093A MD20200093A MD4841B1 MD 4841 B1 MD4841 B1 MD 4841B1 MD A20200093 A MDA20200093 A MD A20200093A MD 20200093 A MD20200093 A MD 20200093A MD 4841 B1 MD4841 B1 MD 4841B1
Authority
MD
Moldova
Prior art keywords
polycyclic
pharmaceutical use
compounds
carbamoylpyridone compounds
carbamoylpyridone
Prior art date
Application number
MDA20200093A
Other languages
English (en)
Russian (ru)
Other versions
MD20200093A2 (ro
Inventor
Хаолунь Цзинь
Скотт Е. Лазервит
Мартин Тереза Алехандра Трехо
Элизабет М. Бейкон
Джероми Дж. Коттелл
Чжэньхун Р. Цай
Хьюн-Цзюн Пюнь
Филип Энтони Морганелли
Минчжэ Цзи
Джеймс Дж. Тейлор
Сяову Чэн
Майкл Р. Миш
Маной К. Десай
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49917297&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD4841(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of MD20200093A2 publication Critical patent/MD20200093A2/ro
Publication of MD4841B1 publication Critical patent/MD4841B1/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Invenţia se referă la compuşi policiclici de carbamoilpiridonă cu următoarea formulă (I):(I),inclusiv stereoizomeri şi săruri acceptabile farmaceutic ale acestora, în care R1, X, W, Y1, Y2, Z1 şi Z4 sunt definiţi în prezentul document. Compuşii revendicaţi pot fi utilizaţi în tratamentul infecţiei cu virusul imunodeficienţei umane (HIV).
MDA20200093A 2012-12-21 2013-12-19 Compuşi policiclici de carbamoilpiridonă şi utilizarea lor farmaceutică MD4841B1 (ro)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261745375P 2012-12-21 2012-12-21
US201361788397P 2013-03-15 2013-03-15
US201361845803P 2013-07-12 2013-07-12
PCT/US2013/076367 WO2014100323A1 (en) 2012-12-21 2013-12-19 Polycyclic-carbamoylpyridone compounds and their pharmaceutical use

Publications (2)

Publication Number Publication Date
MD20200093A2 MD20200093A2 (ro) 2021-05-31
MD4841B1 true MD4841B1 (ro) 2023-01-31

Family

ID=49917297

Family Applications (3)

Application Number Title Priority Date Filing Date
MDA20200093A MD4841B1 (ro) 2012-12-21 2013-12-19 Compuşi policiclici de carbamoilpiridonă şi utilizarea lor farmaceutică
MDA20170067A MD4754C1 (ro) 2012-12-21 2013-12-19 Compuşi policiclici de carbamoilpiridonă şi utilizarea lor farmaceutică
MDA20150064A MD4736C1 (ro) 2012-12-21 2013-12-19 Compus policiclic de carbamoilpiridonă şi utilizarea farmaceutică a acestuia

Family Applications After (2)

Application Number Title Priority Date Filing Date
MDA20170067A MD4754C1 (ro) 2012-12-21 2013-12-19 Compuşi policiclici de carbamoilpiridonă şi utilizarea lor farmaceutică
MDA20150064A MD4736C1 (ro) 2012-12-21 2013-12-19 Compus policiclic de carbamoilpiridonă şi utilizarea farmaceutică a acestuia

Country Status (41)

Country Link
US (6) US9216996B2 (ro)
EP (4) EP3608325B1 (ro)
JP (7) JP6028105B2 (ro)
KR (8) KR101770048B1 (ro)
CN (4) CN107674086B (ro)
AP (1) AP2015008510A0 (ro)
AR (1) AR094197A1 (ro)
AU (6) AU2013361401C1 (ro)
BR (2) BR112015014714B1 (ro)
CA (3) CA2893843C (ro)
CL (3) CL2015001756A1 (ro)
CR (2) CR20170279A (ro)
CY (3) CY1117570T1 (ro)
DK (3) DK3067358T3 (ro)
EA (2) EA037633B1 (ro)
ES (3) ES2753548T3 (ro)
HR (3) HRP20160544T1 (ro)
HU (4) HUE059688T2 (ro)
IL (4) IL239316A (ro)
LT (3) LT3067358T (ro)
LU (1) LUC00083I2 (ro)
MD (3) MD4841B1 (ro)
ME (1) ME02400B (ro)
MX (5) MX372534B (ro)
MY (2) MY191741A (ro)
NL (1) NL300947I2 (ro)
NO (1) NO2018026I1 (ro)
NZ (2) NZ709260A (ro)
PE (2) PE20151499A1 (ro)
PH (3) PH12019501848A1 (ro)
PL (3) PL2822954T3 (ro)
PT (3) PT3067358T (ro)
RS (1) RS54873B1 (ro)
SG (1) SG11201504857SA (ro)
SI (3) SI3067358T1 (ro)
SM (1) SMT201600157B (ro)
TW (5) TWI642669B (ro)
UA (2) UA123572C2 (ro)
UY (1) UY35213A (ro)
WO (1) WO2014100323A1 (ro)
ZA (2) ZA201507997B (ro)

Families Citing this family (179)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2729448B1 (en) 2011-07-06 2015-09-09 Gilead Sciences, Inc. Compounds for the treatment of hiv
DK3632919T3 (da) 2012-04-26 2022-11-14 Bristol Myers Squibb Co Farmaceutiske sammensætninger omfattende imidazothiadiazol- og imidazopyrazinderivater som proteaseaktiverede receptor 4-(par4)- hæmmere til behandling af blodpladeaggregering
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
EA037633B1 (ru) * 2012-12-21 2021-04-23 Джилид Сайэнс, Инк. Полициклические карбамоилпиридоновые соединения, их фармацевтические композиции и применение
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
ES2649156T3 (es) 2013-01-14 2018-01-10 Incyte Holdings Corporation Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim
ES2941292T3 (es) 2013-01-15 2023-05-19 Incyte Holdings Corp Tiazolecarboxamidas y compuestos de piridinecarboxamida útiles como inhibidores de PIM quinasa
NO2865735T3 (ro) 2013-07-12 2018-07-21
CA2916993C (en) 2013-07-12 2019-01-15 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
AR097431A1 (es) 2013-08-23 2016-03-16 Incyte Corp Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de quinasas pim
WO2015177537A1 (en) * 2014-05-20 2015-11-26 Cipla Limited Process for preparing polycyclic carbamoyl pyridone derivatives and intermediates thereof
EP3157915B1 (en) 2014-06-17 2019-02-27 Pfizer Inc Substituted dihydroisoquinolinone compounds
TWI744723B (zh) * 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TW201613936A (en) * 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (ro) * 2014-06-20 2018-06-23
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016027879A1 (ja) * 2014-08-22 2016-02-25 塩野義製薬株式会社 インテグラーゼ阻害活性を有する多環性ピリドン誘導体
US20160067255A1 (en) 2014-09-04 2016-03-10 Gilead Sciences, Inc. Methods of treating or preventing hiv in patients using a combination of tenofovir alafenamide and dolutegravir
WO2016090545A1 (en) 2014-12-09 2016-06-16 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrate inhibitors
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
EA032430B1 (ru) 2014-12-24 2019-05-31 Джилид Сайэнс, Инк. Конденсированные пиримидины для лечения вич
TW202237569A (zh) 2014-12-24 2022-10-01 美商基利科學股份有限公司 喹唑啉化合物
SG11201705184PA (en) 2014-12-24 2017-07-28 Gilead Sciences Inc Isoquinoline compounds for the treatment of hiv
HRP20211456T1 (hr) 2014-12-26 2021-12-24 Emory University Protuvirusni derivati n4-hidroksicitidina
RS56787B1 (sr) 2015-03-04 2018-04-30 Gilead Sciences Inc Toll-like receptor koji modulira jedinjenja 4,6-diamino-pirido[3,2-d]pirimidina
TR201905009T4 (tr) * 2015-04-02 2019-05-21 Gilead Sciences Inc Polisiklik-karbamoilpiridon bileşikleri ve bunların farmasötik kullanımları.
ES2857906T3 (es) * 2015-04-28 2021-09-29 Shionogi & Co Derivado de piridona policíclica contra la influenza y profármaco del mismo
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
EP3341373A1 (en) 2015-08-26 2018-07-04 Gilead Sciences, Inc. Deuterated toll-like receptor modulators
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
NZ741785A (en) 2015-09-30 2019-07-26 Gilead Sciences Inc 3-cyano-1h-1,2,4-triazol-1-yl compounds and uses thereof for the treatment of hiv
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
EA201890654A1 (ru) 2015-11-09 2018-10-31 Джилид Сайэнс, Инк. Терапевтические композиции для лечения вируса иммунодефицита человека
AU2016370591C1 (en) 2015-12-15 2020-09-03 Gilead Sciences, Inc. Human immunodeficiency virus neutralizing antibodies
ES2990061T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros espirocíclicos para la degradación de proteínas diana
WO2017197051A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
EP3454856B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
ES3035041T3 (en) * 2016-06-23 2025-08-27 Viiv Healthcare Co Compositions and methods for the delivery of therapeutics
WO2018005328A1 (en) * 2016-06-27 2018-01-04 Concert Pharmaceuticals, Inc. Deuterated bictegravir
CR20190084A (es) 2016-08-19 2019-05-02 Gilead Sciences Inc Compuestos terapéuticos útiles para el tratamiento profiláctico o terapéutico de una infección por el virus del vih
WO2018042331A1 (en) 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
WO2018042332A1 (en) 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
US10370342B2 (en) 2016-09-02 2019-08-06 Gilead Sciences, Inc. Toll like receptor modulator compounds
US10640499B2 (en) 2016-09-02 2020-05-05 Gilead Sciences, Inc. Toll like receptor modulator compounds
WO2018051250A1 (en) 2016-09-14 2018-03-22 Viiv Healthcare Company Combination comprising tenofovir alafenamide, bictegravir and 3tc
WO2018064071A1 (en) 2016-09-27 2018-04-05 Gilead Sciences, Inc. Therapeutic compositions for treatment of human immunodeficiency virus
EP3519409B1 (en) 2016-09-28 2024-09-18 Gilead Sciences, Inc. Benzothiazol-6-yl acetic acid derivatives and their use for treating hiv infection
EP3532478B1 (en) 2016-10-27 2021-05-26 Gilead Sciences, Inc. Crystalline form of darunavir free base
JOP20190130A1 (ar) 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
CN108250215B (zh) * 2016-12-28 2022-04-19 华创合成制药股份有限公司 一种新型抗hiv药物及其制备方法和用途
TWI784370B (zh) 2017-01-31 2022-11-21 美商基利科學股份有限公司 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
JOP20180009A1 (ar) 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
CN106860464A (zh) * 2017-02-16 2017-06-20 江苏艾迪药业有限公司 用于联合抗病毒治疗的药物组合物及应用
CN106860414B (zh) * 2017-02-16 2019-12-24 江苏艾迪药业股份有限公司 一种用于抗hiv的复方制剂及其制备方法与应用
ZA201803942B (en) 2017-06-13 2021-05-26 Cipla Ltd Novel processes for preparation of integrase inhibitor
EP3641762A4 (en) 2017-06-20 2021-03-10 C4 Therapeutics, Inc. N / O-LINKED DEGRONES AND DEGRONIMERS FOR PROTEIN DEGRADATION
TWI728250B (zh) 2017-06-21 2021-05-21 美商基利科學股份有限公司 靶向hiv gp120及cd3之多特異性抗體
CN110958883A (zh) 2017-06-30 2020-04-03 Viiv保健公司 组合及其用途和疗法
PL3661937T3 (pl) 2017-08-01 2021-12-20 Gilead Sciences, Inc. Formy krystaliczne ((s)-((((2r,5r)-5-(6-amino-9h-puryn-9-ylo)-4-fluoro-2,5-dihydrofuran-2-ylo)oksy)metylo)(fenoksy)fosforylo)-l-alaninianu etylu (gs-9131) do leczenia zakażeń wirusowych
EP3664896A4 (en) 2017-08-09 2021-06-09 VIIV Healthcare Company COMBINATIONS, USES AND CORRESPONDING TREATMENTS
EP3664895A4 (en) 2017-08-09 2021-06-30 VIIV Healthcare Company COMBINATIONS AS WELL AS USES AND TREATMENTS THEREOF
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
TW202024061A (zh) 2017-08-17 2020-07-01 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
JP6924839B2 (ja) * 2017-10-06 2021-08-25 塩野義製薬株式会社 置換された多環性ピリドン誘導体の立体選択的な製造方法
JOP20180092A1 (ar) 2017-10-13 2019-04-13 Gilead Sciences Inc مثبطات hiv بروتياز
EP3700573A1 (en) 2017-10-24 2020-09-02 Gilead Sciences, Inc. Methods of treating patients co-infected with a virus and tuberculosis
SG11202004403QA (en) 2017-12-07 2020-06-29 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
CN111511754B (zh) 2017-12-20 2023-09-12 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
AU2018392213B2 (en) 2017-12-20 2021-03-04 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
US11253524B2 (en) 2018-01-19 2022-02-22 Gilead Sciences, Inc. Metabolites of bictegravir
SI3749673T1 (sl) 2018-02-09 2022-07-29 Sandoz Ag Kristalinična oblika biktegravir natrija
JP7083398B2 (ja) 2018-02-15 2022-06-10 ギリアード サイエンシーズ， インコーポレイテッド ピリジン誘導体およびｈｉｖ感染を処置するためのその使用
WO2019159199A1 (en) 2018-02-16 2019-08-22 Cipla Limited Continues flow process for the preparation of active pharmaceutical ingredients - polycyclic carbamoyl pyridone derivatives and intermediates thereof
EP3752496B1 (en) 2018-02-16 2023-07-05 Gilead Sciences, Inc. Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
CN109020911B (zh) * 2018-04-16 2022-06-28 常州制药厂有限公司 用于制备bictegravir的中间体及其制备方法
EP3784676A1 (en) 2018-04-26 2021-03-03 Mylan Laboratories Ltd. Polymorphic forms of bictegravir and its sodium salt
TW202014193A (zh) 2018-05-03 2020-04-16 捷克科學院有機化學與生物化學研究所 包含碳環核苷酸之2’3’－環二核苷酸
CN110526930B (zh) * 2018-05-23 2022-06-03 莫云芬 抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用
CR20230571A (es) 2018-05-31 2024-01-22 Shionogi & Co DERIVADO POLICÍCLICO DE CARBAMOILPIRIDONA (divisional 2020-0644)
EP3805221A4 (en) 2018-05-31 2022-01-05 Shionogi & Co., Ltd POLYCYCLIC PYRIDONE DERIVATIVE
WO2020004443A1 (ja) 2018-06-27 2020-01-02 国立大学法人北海道大学 多環性カルバモイルピリドン誘導体を含有するアレナウイルス増殖阻害剤
WO2020003151A1 (en) 2018-06-28 2020-01-02 Honour Lab Limited Process for the preparation of sodium (2r,5s,13ar)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1', 2':4,5]pyrazino[2,1-b] [1,3] oxazepin-8-olate and its polymorphic form
LT4257600T (lt) 2018-07-03 2025-06-10 Gilead Sciences, Inc. Antikūnai, nukreipti į gp120, ir jų panaudojimo būdai
US11634431B2 (en) 2018-07-12 2023-04-25 Laurus Labs Limited Process for purification of protected polycyclic carbamoylpyridone derivatives
AU2019307500B2 (en) 2018-07-16 2022-09-29 Gilead Sciences, Inc. Capsid inhibitors for the treatment of HIV
TWI829205B (zh) 2018-07-30 2024-01-11 美商基利科學股份有限公司 抗hiv化合物
EP3852761A1 (en) 2018-09-19 2021-07-28 Gilead Sciences, Inc. Integrase inhibitors for the prevention of hiv
US11179397B2 (en) 2018-10-03 2021-11-23 Gilead Sciences, Inc. Imidazopyrimidine derivatives
IL320867A (en) * 2018-10-22 2025-07-01 Univ Nebraska Antiviral prodrugs and nanoformulations thereof
BR112021008255A2 (pt) 2018-10-31 2021-08-03 Gilead Sciences, Inc. compostos de 6-azabenzimidazol substituídos como inibidores de hpk1
JP7273172B2 (ja) 2018-10-31 2023-05-12 ギリアード サイエンシーズ， インコーポレイテッド Ｈｐｋ１阻害活性を有する置換６－アザベンゾイミダゾール化合物
EP3653629A1 (en) * 2018-11-16 2020-05-20 Sandoz AG Acid addition salts of an integrase strand transfer inhibitor
CN118873676A (zh) 2018-11-29 2024-11-01 内布拉斯加大学董事会 抗病毒前药及其纳米制剂
US12195480B2 (en) 2019-02-07 2025-01-14 Cipla Limited Polymorphs of integrase inhibitor
WO2020176505A1 (en) 2019-02-25 2020-09-03 Gilead Sciences, Inc. Protein kinase c agonists
WO2020176510A1 (en) 2019-02-25 2020-09-03 Gilead Sciences, Inc. Protein kinase c agonists
WO2020178770A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
US11766447B2 (en) 2019-03-07 2023-09-26 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
US12318403B2 (en) 2019-03-07 2025-06-03 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′-cyclic dinucleotides and prodrugs thereof
CN113874079B (zh) 2019-03-22 2024-11-08 吉利德科学公司 桥连三环氨基甲酰基吡啶酮化合物及其药学用途
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202104210A (zh) 2019-04-17 2021-02-01 美商基利科學股份有限公司 Hiv蛋白酶抑制劑
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
WO2020214647A1 (en) 2019-04-17 2020-10-22 Gilead Sciences, Inc. Solid forms of an hiv protease inhibitor
TWI762925B (zh) 2019-05-21 2022-05-01 美商基利科學股份有限公司 鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法
CN110229174A (zh) * 2019-05-22 2019-09-13 博诺康源(北京)药业科技有限公司 Bictegravir原料药基因毒性杂质的合成方法
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
RU2717101C1 (ru) * 2019-06-03 2020-03-18 Андрей Александрович Иващенко Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
CN110263404B (zh) * 2019-06-12 2023-03-21 江苏大学 一种基于dpm模型的一体化预制泵站沉积特性的计算方法
US12486286B2 (en) * 2019-06-18 2025-12-02 Laurus Labs Limited Process and polymorphic forms of bictegravir and its pharmaceutically acceptable salts or co-crystals thereof
US20220305115A1 (en) 2019-06-18 2022-09-29 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
US20200398978A1 (en) 2019-06-20 2020-12-24 Bell Helicopter Textron Inc. Low-drag rotor blade extension
MX2021015452A (es) 2019-06-25 2022-02-11 Gilead Sciences Inc Proteinas de fusion flt3l-fc y metodos de uso.
US11248005B2 (en) 2019-07-08 2022-02-15 Lupin Limited Process for preparation of intermediates used for the synthesis of HIV integrase inhibitor
CA3145791A1 (en) 2019-07-16 2021-01-21 Gilead Sciences, Inc. Hiv vaccines and methods of making and using
WO2021011891A1 (en) 2019-07-18 2021-01-21 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
US20220296619A1 (en) 2019-08-19 2022-09-22 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
CN110698473B (zh) * 2019-10-08 2020-12-18 浙江大学 哌嗪酮并羟基吡啶酮-5-羧基类化合物及制备和应用
KR20220106165A (ko) 2019-11-26 2022-07-28 길리애드 사이언시즈, 인코포레이티드 Hiv의 예방을 위한 캡시드 억제제
US20230059640A1 (en) 2019-11-28 2023-02-23 Shionogi & Co., Ltd. Prophylactic and therapeutic pharmaceutical agent for hiv infectious diseases characterized by comprising combination of integrase inhibitor and anti-hiv agent
WO2021107065A1 (ja) * 2019-11-28 2021-06-03 塩野義製薬株式会社 多環性ピリドピラジン誘導体
EP4445902A3 (en) 2019-12-24 2024-12-18 Carna Biosciences, Inc. Diacylglycerol kinase modulating compounds
EP4110783A1 (en) 2020-02-24 2023-01-04 Gilead Sciences, Inc. Tetracyclic compounds for treating hiv infection
JP2023518433A (ja) 2020-03-20 2023-05-01 ギリアード サイエンシーズ， インコーポレイテッド ４’－ｃ－置換－２－ハロ－２’－デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法
WO2021236944A1 (en) 2020-05-21 2021-11-25 Gilead Sciences, Inc. Pharmaceutical compositions comprising bictegravir
CN113698420A (zh) * 2020-05-22 2021-11-26 上海迪赛诺生物医药有限公司 比克替拉韦钠的新晶型及其制备方法
KR20230027275A (ko) 2020-06-25 2023-02-27 길리애드 사이언시즈, 인코포레이티드 Hiv 치료용 캡시드 저해제
EP4192474B1 (en) 2020-08-07 2025-09-10 Gilead Sciences, Inc. Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
WO2022072520A1 (en) * 2020-09-30 2022-04-07 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
CN114426540B (zh) * 2020-10-29 2024-04-26 上海拓界生物医药科技有限公司 吡啶并[1,2-a]吡嗪-1,8-二酮类前药衍生物、其制备方法及其应用
TW202227445A (zh) * 2020-10-30 2022-07-16 大陸商上海拓界生物醫藥科技有限公司 抑制基因缺陷的ｈｉｖ病毒的用途
CN116437958A (zh) 2020-11-11 2023-07-14 吉利德科学公司 鉴定对采用gp120 CD4结合位点导向的抗体的疗法敏感的HIV患者的方法
DK4196479T5 (da) 2021-01-19 2025-01-02 Gilead Sciences Inc Substituerede pyridotriazinforbindelser og anvendelser deraf
WO2022157561A1 (en) * 2021-01-22 2022-07-28 Laurus Labs Limited Processes for purification of bictegravir intermediates
CN114835730A (zh) * 2021-02-02 2022-08-02 齐鲁制药有限公司 一种制备多环氨基甲酰基吡啶酮化合物的方法
US12187740B2 (en) 2021-04-19 2025-01-07 Honour Lab Limited Polymorphic forms of bictegravir potassium
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
EP4359411A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20240005901A (ko) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
KR20240023629A (ko) 2021-06-23 2024-02-22 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
CR20230585A (es) 2021-06-23 2024-02-19 Gilead Sciences Inc Compuestos Moduladores de Diacilglicerol Quinasa.
WO2023006087A1 (zh) * 2021-07-30 2023-02-02 南京明德新药研发有限公司 大环吡啶酮类化合物及其应用
CN114230579A (zh) * 2021-11-12 2022-03-25 南京艾迪医药科技有限公司 多环氨基甲酰基吡啶酮衍生物及其制备方法和药物组合物
EP4440700A1 (en) 2021-12-03 2024-10-09 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
KR20240113832A (ko) 2021-12-03 2024-07-23 길리애드 사이언시즈, 인코포레이티드 Hiv 바이러스 감염 치료용 화합물
PT4445900T (pt) 2021-12-03 2025-08-13 Gilead Sciences Inc Compostos terapêuticos para a infecção pelo vírus do hiv
CN114605437A (zh) * 2022-04-01 2022-06-10 遵义医科大学 连续一锅法制备三个替拉韦药物的合成工艺
TWI843506B (zh) 2022-04-06 2024-05-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2023248240A1 (en) 2022-06-21 2023-12-28 Mylan Laboratories Limited Polymorphic forms of bictegravir sodium
TWI867601B (zh) 2022-07-01 2024-12-21 美商基利科學股份有限公司 可用於ｈｉｖ病毒感染之疾病預防性或治療性治療的治療性化合物
JP2025523043A (ja) 2022-07-12 2025-07-17 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖ免疫原性ポリペプチド及びワクチン、並びにその使用
CN119768183A (zh) 2022-08-26 2025-04-04 吉利德科学公司 用于广泛中和抗体的给药和安排方案
WO2024061257A1 (zh) * 2022-09-20 2024-03-28 吉斯凯(苏州)制药有限公司 多环氮杂环酮类化合物及其应用
WO2024076915A1 (en) 2022-10-04 2024-04-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use
TW202444363A (zh) 2023-04-19 2024-11-16 美商基利科學股份有限公司 殼體抑制劑之給藥方案
US20250042926A1 (en) 2023-05-31 2025-02-06 Gilead Sciences, Inc. Therapeutic compounds for hiv
WO2024249517A1 (en) 2023-05-31 2024-12-05 Gilead Sciences, Inc. Anti-hiv compounds
US20250011352A1 (en) 2023-05-31 2025-01-09 Gilead Sciences, Inc. Solid forms
WO2025029247A1 (en) 2023-07-28 2025-02-06 Gilead Sciences, Inc. Weekly regimen of lenacapavir for the treatment and prevention of hiv
EP4529922A1 (en) 2023-09-29 2025-04-02 Gilead Sciences, Inc. Pharmaceutical formulations of bictegravir and lenacapavir
TW202513072A (zh) 2023-08-15 2025-04-01 美商基利科學股份有限公司 比替拉韋及利那卡帕韋之醫藥配方
WO2025042394A1 (en) 2023-08-23 2025-02-27 Gilead Sciences, Inc. Dosing regimen of hiv capsid inhibitor
WO2025076542A1 (en) 2023-10-05 2025-04-10 Jones R Brad Atovaquone as an ros inducer for use in the elimination of hiv-infected t-cells
US20250127801A1 (en) 2023-10-11 2025-04-24 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
TW202530227A (zh) 2023-10-11 2025-08-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
US20250120989A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
WO2025137245A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
WO2025184609A1 (en) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Antiviral compounds
WO2025184447A1 (en) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors
US20250289822A1 (en) 2024-03-01 2025-09-18 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
US20250326779A1 (en) 2024-04-03 2025-10-23 Gilead Sciences, Inc. Anti-hiv compounds
WO2025260028A1 (en) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors

Family Cites Families (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE788516A (fr) 1971-09-10 1973-03-07 Lonza Ag Procede de fabrication d'esters alcoxyacetylacetiques
GB1528382A (en) 1974-12-26 1978-10-11 Teijin Ltd Cyclopentene diols and acyl esters thereof and processes for their preparation
DE2658401A1 (de) 1976-12-23 1978-07-06 Merck Patent Gmbh Cyclopentan-1-amine, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel
US4575694A (en) 1984-03-05 1986-03-11 Allied Corporation Coaxial connector
DE3900735A1 (de) 1989-01-12 1990-07-26 Hoechst Ag Neue mehrfunktionelle (alpha)-diazo-(beta)-ketoester, verfahren zu ihrer herstellung und deren verwendung
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
DE4014649A1 (de) 1990-05-08 1991-11-14 Hoechst Ag Neue mehrfunktionelle verbindungen mit (alpha)-diazo-ss-ketoester- und sulfonsaeureester-einheiten, verfahren zu ihrer herstellung und deren verwendung
GB9301000D0 (en) 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
SE9702772D0 (sv) 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
AU1403099A (en) 1997-11-14 1999-06-07 Merck & Co., Inc. Alpha-1a adrenergic receptor antagonists
JP2002529455A (ja) 1998-11-09 2002-09-10 ジェームズ・ブラック・ファウンデーション・リミテッド ガストリンおよびコレシストキニン受容体リガンド類
GB2345058A (en) 1998-12-01 2000-06-28 Cerebrus Pharm Ltd Hydroxypyridone compounds useful in the treatment of oxidative damage to the central nervous system
DE69939749D1 (de) 1998-12-25 2008-11-27 Shionogi & Co Aromatische heterocyclen mit hiv integrase inhibierenden eigenschaften
AU2001262732A1 (en) 2000-06-14 2001-12-24 Shionogi And Co., Ltd. Inhibitor for enzyme having two divalent metal ions as active centers
AU1532802A (en) * 2000-10-12 2002-04-22 Merck & Co Inc Aza- and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors
ATE530520T1 (de) 2001-08-10 2011-11-15 Shionogi & Co Antivirales mittel
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US6727275B2 (en) 2001-10-03 2004-04-27 Ucb, S.A./N.V. Pyrrolidinone derivatives
CA2463976C (en) 2001-10-26 2007-02-13 Benedetta Crescenzi N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
WO2004004657A2 (en) 2002-07-09 2004-01-15 Bristol-Myers Squibb Company Hiv integrase inhibitors
CA2498111A1 (en) 2002-09-11 2004-03-25 Merck & Co., Inc. Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors
CA2470365C (en) 2002-11-20 2011-05-17 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
PL408254A1 (pl) * 2003-01-14 2014-07-21 Gilead Sciences Inc. Kompozycje i i sposoby wykorzystywane w skojarzonej terapii przeciwwirusowej
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
TW200528440A (en) 2003-10-31 2005-09-01 Fujisawa Pharmaceutical Co 2-cyanopyrrolidinecarboxamide compound
CN101014571A (zh) 2004-01-30 2007-08-08 默克公司 用作hiv整合酶抑制剂的n－苄基－3,4－二羟基吡啶－2－羧酰胺类和n－苄基－2,3－二羟基吡啶－4－羧酰胺类化合物
JP4859676B2 (ja) 2004-02-11 2012-01-25 スミスクライン ビーチャム コーポレーション Ｈｉｖインテグラーゼ阻害剤
US7619086B2 (en) 2004-03-09 2009-11-17 Merck & Co., Inc. HIV integrase inhibitors
WO2005110399A2 (en) 2004-04-29 2005-11-24 The Regents Of The University Of California Zinc-binding groups for metalloprotein inhibitors
EP1755586A2 (en) 2004-04-29 2007-02-28 The Regents of the University of California Hydroxypyridinone, hydroxypyridinethione, pyrone, and thiopyrone metalloprotein inhibitors
CA2564372C (en) 2004-05-07 2011-10-11 Merck & Co., Inc. Hiv integrase inhibitors
US7273859B2 (en) 2004-05-12 2007-09-25 Bristol-Myers Squibb Company HIV integrase inhibitors: cyclic pyrimidinone compounds
CN1953751A (zh) * 2004-05-17 2007-04-25 泰博特克药品有限公司 取代的1－苯基－1,5－二氢－吡啶并－[3,2－b]吲哚－2－酮和其它的hiv抑制剂的组合物
MY134672A (en) 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
WO2005113509A1 (en) 2004-05-20 2005-12-01 Japan Tobacco Inc. Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
US8633219B2 (en) 2004-05-21 2014-01-21 Japan Tobacco Inc. Combination therapy
EP1790638B1 (en) 2004-09-15 2013-04-03 Shionogi Co., Ltd. Carbamoylpyridone derivative having hiv integrase inhibitory activity
JP2006118669A (ja) 2004-10-25 2006-05-11 Sanoh Industrial Co Ltd 樹脂チューブ
WO2006066414A1 (en) 2004-12-23 2006-06-29 Virochem Pharma Inc. Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase
WO2006088173A1 (ja) 2005-02-21 2006-08-24 Shionogi & Co., Ltd. Ｈｉｖインテグラーゼ阻害活性を有する２環性カルバモイルピリドン誘導体
PT3284520T (pt) 2005-04-28 2019-09-10 Shionogi & Co Derivado policíclico de carbamoílpiridona possuindo atividade inibidora de integrase do hiv
TW200716632A (en) 2005-05-16 2007-05-01 Gilead Sciences Inc Integrase inhibitor compounds
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
EP1906971A2 (en) 2005-07-27 2008-04-09 Gilead Sciences, Inc. Antiviral compounds
WO2007049675A1 (ja) 2005-10-27 2007-05-03 Shionogi & Co., Ltd. Ｈｉｖインテグラーゼ阻害活性を有する多環性カルバモイルピリドン誘導体
CA2847871C (en) 2005-12-30 2016-07-26 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
US7601844B2 (en) 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
WO2007089030A1 (en) 2006-02-01 2007-08-09 Japan Tobacco Inc. Use of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or salt thereof for treating retrovirus infection
IN2014CN00613A (ro) 2006-03-06 2015-08-21 Japan Tobacco Inc
WO2007102499A1 (ja) 2006-03-06 2007-09-13 Japan Tobacco Inc. ４－オキソキノリン化合物の製造方法
US7893055B2 (en) 2006-06-28 2011-02-22 Bristol-Myers Squibb Company HIV integrase inhibitors
EP2046328A4 (en) 2006-07-19 2009-10-28 Univ Georgia Res Found PYRIDINONE DIKETOIC ACIDS: INHIBITORS OF HIV REPLICATION IN COMBINATION THERAPY
ES2536923T3 (es) 2006-09-12 2015-05-29 Gilead Sciences, Inc. Proceso e intermedios para preparar inhibidores de la integrasa del VIH
EP2084160A1 (en) 2006-10-18 2009-08-05 Merck & Co., Inc. Hiv integrase inhibitors
LT2487166T (lt) 2007-02-23 2016-11-10 Gilead Sciences, Inc. Terapinių agentų farmakokinetinių savybių moduliatoriai
US20080280945A1 (en) 2007-05-09 2008-11-13 Sachin Lohani Crystalline forms of an HIV integrase inhibitor
AR067184A1 (es) 2007-06-29 2009-09-30 Gilead Sciences Inc Uso de 6-(3-cloro-2-fluorbencil)-1-[(2s)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxilico. composicion farmaceutica
CN101686972B (zh) 2007-06-29 2013-08-14 吉里德科学公司 治疗用组合物和方法
US20090012103A1 (en) 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
US20090258939A1 (en) 2007-07-31 2009-10-15 Wendye Robbins Pyrone analog compositions and methods
AR068403A1 (es) 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
EA201200631A1 (ru) 2007-11-16 2012-11-30 Джилид Сайенсиз, Инк. Ингибиторы репликации вируса иммунодефицита человека
GB0803019D0 (en) 2008-02-19 2008-03-26 Btg Int Ltd Fluorinated compounds
US8129398B2 (en) 2008-03-19 2012-03-06 Bristol-Myers Squibb Company HIV integrase inhibitors
US20100272811A1 (en) 2008-07-23 2010-10-28 Alkermes,Inc. Complex of trospium and pharmaceutical compositions thereof
WO2010011815A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
WO2010011819A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
WO2010011818A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
EP2330902B1 (en) * 2008-07-25 2012-11-14 GlaxoSmithKline LLC Chemical compounds
EP2320909B8 (en) 2008-07-25 2016-03-30 VIIV Healthcare Company Chemical compounds
EP2320908B9 (en) 2008-07-25 2014-06-18 VIIV Healthcare Company Dolutegravir Prodrugs
JP5572168B2 (ja) 2008-12-11 2014-08-13 ビーブ・ヘルスケア・カンパニー カルバモイルピリドンｈｉｖインテグラーゼ阻害剤の製造方法および中間体
EP3210603A1 (en) * 2008-12-11 2017-08-30 Shionogi & Co., Ltd Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
JP2012512246A (ja) 2008-12-17 2012-05-31 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ環修飾型三環式ベンゾナフチリジノン・タンパク質キナーゼ阻害薬及びこれらの使用
MX2011008289A (es) 2009-02-06 2011-09-15 Gilead Sciences Inc Tabletas para terapia combinada.
TWI518084B (zh) * 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
EP2412708A4 (en) 2009-03-26 2014-07-23 Shionogi & Co SUBSTITUTED 3-HYDROXY-4-PYRIDONE DERIVATIVE
TR201808501T4 (tr) 2009-06-15 2018-07-23 Shionogi & Co Sübstitüe polisiklik karbamoilpiridon türevi.
WO2011011483A1 (en) * 2009-07-22 2011-01-27 Glaxosmithkline Llc Chemical compounds
WO2011028044A2 (ko) 2009-09-02 2011-03-10 이화여자대학교 산학협력단 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물
CA2967453C (en) 2010-01-27 2018-07-17 Viiv Healthcare Company Combinations for use in the inhibition of hiv-1
NZ601847A (en) 2010-02-26 2014-03-28 Japan Tobacco Inc 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv integrase inhibitor
TWI582097B (zh) * 2010-03-23 2017-05-11 Ｖｉｉｖ醫療保健公司 製備胺甲醯吡啶酮衍生物及中間體之方法
WO2011139637A1 (en) 2010-05-03 2011-11-10 Philadelphia Health & Education Corporation Small-molecule modulators of hiv-1 capsid stability and methods thereof
AU2011274322B2 (en) 2010-07-02 2015-08-13 Gilead Sciences, Inc. Naphth- 2 -ylacetic acid derivatives to treat AIDS
BR112012033689A2 (pt) 2010-07-02 2019-09-24 Gilead Sciences Inc derivados de ácido 2-quinolinil-acético como compostos de hiv antivirais
EP2595986A2 (en) 2010-07-14 2013-05-29 Addex Pharma SA Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors
SG187683A1 (en) 2010-08-05 2013-03-28 Shionogi & Co Process for preparing compound having hiv integrase inhibitory activity
BR112013006722B1 (pt) 2010-09-24 2020-11-03 Shionogi & Co., Ltd profármaco de derivado de carbamoilpiridona policíclica substituída
CN106511357A (zh) 2010-11-19 2017-03-22 吉利德科学公司 包含利匹韦林HCl和富马酸替诺福韦酯的治疗组合物
WO2012106534A2 (en) 2011-02-02 2012-08-09 The Regents Of The University Of California Hiv integrase inhibitors
EA024952B1 (ru) 2011-04-21 2016-11-30 Джилид Сайэнс, Инк. Бензотиазолы и их применение для лечения вич-инфекции
WO2012151361A1 (en) 2011-05-03 2012-11-08 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
US9328075B2 (en) 2011-05-05 2016-05-03 St. Jude Children's Research Hospital Pyrimidinone compounds and methods for treating influenza
US9121496B2 (en) 2011-06-29 2015-09-01 Arvinmeritor Technology, Llc Drive axle system and a method of control
EP2729448B1 (en) 2011-07-06 2015-09-09 Gilead Sciences, Inc. Compounds for the treatment of hiv
CN103826616B (zh) 2011-07-07 2016-08-10 爱尔兰詹森科学公司 地瑞纳韦组合配制品
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
WO2013038407A1 (en) 2011-09-14 2013-03-21 Mapi Pharma Ltd. Amorphous form of dolutegravir
AU2012321762A1 (en) 2011-10-12 2014-04-17 Shionogi & Co., Ltd. Polycyclic pyridone derivative having integrase-inhibiting activity
US9643974B2 (en) 2011-12-12 2017-05-09 Bayer Intellectual Property Gmbh Amino-substituted imidazopyridazines
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
WO2014008636A1 (en) 2012-07-11 2014-01-16 Merck Sharp & Dohme Corp. Macrocyclic compounds as hiv integrase inhibitors
EP2875024A4 (en) 2012-07-20 2015-12-23 Merck Sharp & Dohme HIV TREATMENT WITH AMIDOSUBSTITUTED PYRIMIDINONE DERIVATIVES
WO2014018449A1 (en) 2012-07-25 2014-01-30 Merck Sharp & Dohme Corp. Substituted naphthyridinedione derivatives as hiv integrase inhibitors
IN2015DN01688A (ro) 2012-08-03 2015-07-03 Gilead Sciences Inc
MX2015005562A (es) 2012-11-08 2015-07-23 Squibb Bristol Myers Co Compuestos de piridilo sustituidos con heteroarilo utiles como moduladores de cinasa.
MX2015007563A (es) 2012-12-14 2015-10-14 Glaxosmithkline Llc Composiciones farmaceuticas.
US9714243B2 (en) 2012-12-17 2017-07-25 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as HIV integrase inhibitors
EA037633B1 (ru) * 2012-12-21 2021-04-23 Джилид Сайэнс, Инк. Полициклические карбамоилпиридоновые соединения, их фармацевтические композиции и применение
US20160000721A1 (en) 2012-12-21 2016-01-07 Merck Sharp & Dohme Corp. Gastro-retentive formulations
US20140221355A1 (en) 2012-12-21 2014-08-07 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
TW201431859A (zh) 2012-12-27 2014-08-16 Japan Tobacco Inc 經取代之螺吡啶並［１，２－ａ］吡□衍生物及該衍生物作爲ＨＩＶ整合酶抑制劑之醫藥用途
US9493479B2 (en) 2013-04-16 2016-11-15 Merck Sharp & Dohme Corp. Substituted pyrido[1,2-a]pyrazines as HIV integrase inhibitors
WO2014200880A1 (en) 2013-06-13 2014-12-18 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
NO2865735T3 (ro) 2013-07-12 2018-07-21
CA2916993C (en) 2013-07-12 2019-01-15 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
WO2015039348A1 (en) 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
MD4794B1 (ro) 2013-09-27 2022-02-28 Merck Sharp & Dohme Corp Derivaţi de chinolizină substituiţi utili ca inhibitori de integrază HIV
WO2015089847A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
US9856271B2 (en) 2014-01-21 2018-01-02 Laurus Labs Limited Process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (ro) 2014-06-20 2018-06-23
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
PT3166607T (pt) * 2014-07-11 2022-12-07 Gilead Sciences Inc Moduladores de receptores de tipo toll para o tratamento do vih
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
WO2016102078A1 (en) 2014-12-24 2016-06-30 Ratiopharm Gmbh Solid state forms of dolutegravir sodium
TR201905009T4 (tr) 2015-04-02 2019-05-21 Gilead Sciences Inc Polisiklik-karbamoilpiridon bileşikleri ve bunların farmasötik kullanımları.
PL4070788T3 (pl) 2015-06-30 2023-07-10 Gilead Sciences, Inc. Formulacje farmaceutyczne
CA2921336A1 (en) 2015-06-30 2016-12-30 Gilead Sciences, Inc. Pharmaceutical formulations
EA201890654A1 (ru) 2015-11-09 2018-10-31 Джилид Сайэнс, Инк. Терапевтические композиции для лечения вируса иммунодефицита человека

Also Published As

Publication number Publication date
PL3067358T3 (pl) 2020-02-28
LT3067358T (lt) 2019-11-25
KR20200067930A (ko) 2020-06-12
TW202212342A (zh) 2022-04-01
NZ718708A (en) 2018-11-30
KR20170073733A (ko) 2017-06-28
US9663528B2 (en) 2017-05-30
CA3131094A1 (en) 2014-06-26
KR101770048B1 (ko) 2017-08-21
US20170260204A1 (en) 2017-09-14
KR102351912B1 (ko) 2022-01-17
NZ709260A (en) 2016-07-29
KR20190124814A (ko) 2019-11-05
CY2018022I1 (el) 2019-07-10
PT3608325T (pt) 2022-10-17
CN107674086A (zh) 2018-02-09
EA201890236A1 (ru) 2018-10-31
LTPA2018511I1 (lt) 2018-10-10
CA2893843C (en) 2018-09-04
PE20170528A1 (es) 2017-05-28
TWI693224B (zh) 2020-05-11
CL2017001191A1 (es) 2018-02-09
CL2016000837A1 (es) 2016-10-21
TWI815245B (zh) 2023-09-11
MY164352A (en) 2017-12-15
HRP20160544T1 (hr) 2016-07-15
AU2016262722B2 (en) 2018-10-18
AU2016262722A1 (en) 2016-12-08
AU2013361401C1 (en) 2018-08-09
PT3067358T (pt) 2019-11-18
UA114351C2 (uk) 2017-05-25
JP6411409B2 (ja) 2018-10-24
KR20220080208A (ko) 2022-06-14
PL3608325T3 (pl) 2022-11-07
SG11201504857SA (en) 2015-07-30
US20190092787A1 (en) 2019-03-28
BR122015029881B1 (pt) 2022-04-26
US20170057976A1 (en) 2017-03-02
HRP20220899T1 (hr) 2022-10-28
RS54873B1 (sr) 2016-10-31
CN104995198A (zh) 2015-10-21
ES2926068T3 (es) 2022-10-21
EA201591027A1 (ru) 2016-05-31
KR102246963B1 (ko) 2021-04-30
CN111303152A (zh) 2020-06-19
AU2013361401B2 (en) 2017-01-05
MX2022013596A (es) 2022-11-16
KR102527797B1 (ko) 2023-05-03
MX2015008009A (es) 2015-10-22
MD4736B1 (ro) 2020-12-31
SI3608325T1 (sl) 2022-09-30
PH12019501848A1 (en) 2020-03-02
TW201441224A (zh) 2014-11-01
CR20150380A (es) 2015-08-21
CA3012242A1 (en) 2014-06-26
EP4122935A1 (en) 2023-01-25
IL247311A0 (en) 2016-09-29
BR112015014714B1 (pt) 2018-12-26
JP6028105B2 (ja) 2016-11-16
AU2020202914B2 (en) 2021-09-09
TWI752457B (zh) 2022-01-11
HUE059688T2 (hu) 2022-12-28
CA3012242C (en) 2021-11-02
KR20210049956A (ko) 2021-05-06
PH12016500389A1 (en) 2018-10-01
UY35213A (es) 2014-06-30
AU2021221427B2 (en) 2023-10-12
TW201918485A (zh) 2019-05-16
PH12015501445A1 (en) 2015-09-14
PT2822954E (pt) 2016-06-16
AU2020202914A1 (en) 2020-05-21
EP3608325B1 (en) 2022-07-06
PL2822954T3 (pl) 2016-09-30
EP2822954A1 (en) 2015-01-14
JP2021193090A (ja) 2021-12-23
ES2753548T3 (es) 2020-04-13
IL274988A (en) 2020-07-30
PH12015501445B1 (en) 2015-09-14
BR122015029881A2 (pt) 2016-03-22
MY191741A (en) 2022-07-13
EA030003B1 (ru) 2018-06-29
JP7301918B2 (ja) 2023-07-03
MX372534B (es) 2020-03-23
US20160176885A1 (en) 2016-06-23
JP2016179996A (ja) 2016-10-13
CY1122246T1 (el) 2020-11-25
LT3608325T (lt) 2022-09-12
ME02400B (me) 2016-09-20
IL239316A (en) 2016-09-29
CN111303152B (zh) 2023-04-11
AR094197A1 (es) 2015-07-15
CL2015001756A1 (es) 2015-08-07
IL245780B (en) 2019-02-28
HUE028284T2 (en) 2016-12-28
ZA201507997B (en) 2019-09-25
MD4754C1 (ro) 2021-12-31
MD4736C1 (ro) 2021-07-31
MD20150064A2 (ro) 2015-11-30
IL245780A0 (en) 2016-08-02
WO2014100323A1 (en) 2014-06-26
EA037633B1 (ru) 2021-04-23
EP3067358B1 (en) 2019-08-07
EP3608325A1 (en) 2020-02-12
TWI830624B (zh) 2024-01-21
DK3067358T3 (da) 2019-11-04
DK2822954T3 (en) 2016-05-30
HK1250711A1 (zh) 2019-01-11
JP6571256B2 (ja) 2019-09-04
ES2577283T3 (es) 2016-07-14
US9216996B2 (en) 2015-12-22
AU2013361401A1 (en) 2015-08-27
PE20151499A1 (es) 2015-10-29
US11548901B2 (en) 2023-01-10
JP2023134483A (ja) 2023-09-27
HUS1800035I1 (hu) 2018-09-28
JP2025138660A (ja) 2025-09-25
CA2893843A1 (en) 2014-06-26
CR20170279A (es) 2017-10-19
TWI642669B (zh) 2018-12-01
HK1205124A1 (en) 2015-12-11
BR112015014714A2 (pt) 2016-01-05
JP2019218368A (ja) 2019-12-26
AU2018232957B2 (en) 2020-01-30
AU2021221427A1 (en) 2021-09-16
KR20150096504A (ko) 2015-08-24
LUC00083I2 (en) 2018-10-15
PH12016500389B1 (en) 2018-10-01
US10689399B2 (en) 2020-06-23
KR20220011789A (ko) 2022-01-28
IL239316A0 (en) 2015-07-30
CY2018022I2 (el) 2019-07-10
LTC2822954I2 (lt) 2019-10-10
CN104995198B (zh) 2018-01-30
KR102406288B1 (ko) 2022-06-13
SI2822954T1 (sl) 2016-07-29
KR102040007B1 (ko) 2019-11-05
TW202400591A (zh) 2024-01-01
HK1216643A1 (zh) 2016-11-25
EP3067358A1 (en) 2016-09-14
JP2016508134A (ja) 2016-03-17
CN116640140A (zh) 2023-08-25
MX2020003055A (es) 2020-07-27
CN107674086B (zh) 2020-03-31
MD20200093A2 (ro) 2021-05-31
SI3067358T1 (sl) 2019-12-31
AU2018232957A1 (en) 2018-10-11
HUE046559T2 (hu) 2020-03-30
CY1117570T1 (el) 2017-04-26
HRP20191957T1 (hr) 2020-02-07
DK3608325T3 (da) 2022-08-22
AP2015008510A0 (en) 2015-06-30
MD4754B1 (ro) 2021-05-31
UA123572C2 (uk) 2021-04-28
US20210053988A1 (en) 2021-02-25
AU2023286038A1 (en) 2024-01-25
KR102120875B1 (ko) 2020-06-09
EP2822954B1 (en) 2016-03-09
JP6933690B2 (ja) 2021-09-08
KR20230061576A (ko) 2023-05-08
US10035809B2 (en) 2018-07-31
NL300947I2 (nl) 2018-09-26
JP2019023204A (ja) 2019-02-14
SMT201600157B (it) 2016-08-31
NO2018026I2 (no) 2018-08-23
ZA201903516B (en) 2020-01-29
MX357940B (es) 2018-07-31
US20140221356A1 (en) 2014-08-07
US9732092B2 (en) 2017-08-15
MX344879B (es) 2017-01-11
TW202104229A (zh) 2021-02-01
NO2018026I1 (no) 2018-08-23

Similar Documents

Publication Publication Date Title
MD4841B1 (ro) Compuşi policiclici de carbamoilpiridonă şi utilizarea lor farmaceutică
NZ732391A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
PH12015501156A1 (en) Pharmaceutical compositions
PH12015502539B1 (en) Cenicriviroc compositions and methods of making and using the same
CY1119544T1 (el) Πολυκυκλικες ενωσεις καραβαμοϋλοπυριδονης και χρηση αυτων στη θεραπεια λοιμωξεων απο hiv
EA201791872A1 (ru) Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение
MX2016004492A (es) Inhibidores de la replicacion del virus de inmunodeficiencia humana (vih).
MY173422A (en) Purine derivatives for the treatment of viral infections
MY169159A (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
IN2011CH03893A (ro)
IN2013CH05288A (ro)
PL401956A1 (pl) Pochodne 1,2,4-triazolo-5-tionu oraz ich zastosowanie

Legal Events

Date Code Title Description
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)